Cargando…
Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls
Cognitive dysfunction is common in depression during both acute episodes and remission. Vortioxetine is a novel multimodal antidepressant that has improved cognitive function including executive function in depressed patients in randomised placebo-controlled clinical trials. However, it is unclear w...
Autores principales: | Smith, J, Browning, M, Conen, S, Smallman, R, Buchbjerg, J, Larsen, K G, Olsen, C K, Christensen, S R, Dawson, G R, Deakin, J F, Hawkins, P, Morris, R, Goodwin, G, Harmer, C J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984095/ https://www.ncbi.nlm.nih.gov/pubmed/28533517 http://dx.doi.org/10.1038/mp.2017.104 |
Ejemplares similares
-
Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant
por: Chen, Grace, et al.
Publicado: (2013) -
Which Cognitive Domains are Improved by Treatment with Vortioxetine?
por: Harrison, John E, et al.
Publicado: (2016) -
Neuroinflammation as measured by positron emission tomography in patients with recent onset and established schizophrenia: implications for immune pathogenesis
por: Conen, Silke, et al.
Publicado: (2020) -
Effectiveness of vortioxetine in real-world clinical practice: Interim results from the relieve study
por: Mattingly, G., et al.
Publicado: (2021) -
Efficacy of vortioxetine on the physical symptoms of major depressive
disorder
por: Christensen, Michael Cronquist, et al.
Publicado: (2018)